Moderna’s Suit Against Pfizer Could Result In ‘Modest Royalties’ Paid By Both Rivals
Executive Summary
Moderna seeks damages for sales of Comirnaty in US and other wealthy countries from 8 March onward, a timeframe driven by Moderna's accessibility pledge. Suit claims Pfizer and BioNTech copied two key features of its mRNA technology for their rival COVID vaccine.
You may also be interested in...
GSK Seeks To Prevent Pfizer From Selling Its Rival RSV Vaccine In the US
Claiming Pfizer’s Abrysvo infringes four of its patents, GSK asks court to permanently enjoin Pfizer from making or selling the vaccine in the US but would exempt the pending maternal indication.
New Patent Battles Emerge Over What Lipid Technology Is Used In mRNA COVID-19 Vaccines
Alnylam seeks royalties, claiming its lipid nanoparticle technology is a component of both Moderna’s and Pfizer’s vaccines. Moderna calls Alnylam’s suit ‘blatant opportunism.’ Acuitas sues Arbutus seeking declaratory judgement that Comirnaty does not infringe its LPN technology.
Moderna Again Faces Claims It Excluded Others’ Work In Developing COVID-19 Vaccine
Arbutus Biopharma alleges Moderna refused to license patents covering its lipid nanoparticle delivery platform in developing Spikevax. Moderna says it created its own proprietary LNP delivery technology.